BR0316039A - Precursor de n-acetilgalactosamina-4-sulfatase, métodos de tratamento usando a enzima e métodos para produção e purificação da enzima - Google Patents
Precursor de n-acetilgalactosamina-4-sulfatase, métodos de tratamento usando a enzima e métodos para produção e purificação da enzimaInfo
- Publication number
- BR0316039A BR0316039A BR0316039-4A BR0316039A BR0316039A BR 0316039 A BR0316039 A BR 0316039A BR 0316039 A BR0316039 A BR 0316039A BR 0316039 A BR0316039 A BR 0316039A
- Authority
- BR
- Brazil
- Prior art keywords
- enzyme
- methods
- acetylgalactosamine
- sulfatase
- precursor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 102000004190 Enzymes Human genes 0.000 title abstract 4
- 108090000790 Enzymes Proteins 0.000 title abstract 4
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 title abstract 3
- 102000018740 N-Acetylgalactosamine-4-Sulfatase Human genes 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title abstract 2
- 102000010911 Enzyme Precursors Human genes 0.000 title 1
- 108010062466 Enzyme Precursors Proteins 0.000 title 1
- 239000002243 precursor Substances 0.000 abstract 4
- 101000923070 Homo sapiens Arylsulfatase B Proteins 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06012—N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
"PRECURSOR DE N-ACETILGALACTOSAMINA-4-SULFATASE, MéTODOS DE TRATAMENTO USANDO A ENZIMA E MéTODOS PARA PRODUçãO E PURIFICAçãO DA ENZIMA". A presente invenção fornece uma N-acetilgalactosamina-4-sulfatase precursora humana recombinante altamente purificada e seus mutantes, fragmentos ou análogos biologicamente ativos, assim como formulações farmacêuticas compreendendo N-acetilgalactosamina-4-sulfatase precursora humana recombinante altamente purificada. A invenção também fornece métodos para o tratamento de doenças causadas, no todo ou em parte, por deficiências em N-acetilgalactosamina-4-sulfatase humana, incluindo MPS VI, e métodos para produzir e purificar a enzima precursora recombinante para produzir uma forma altamente purificada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/290,908 US6866844B2 (en) | 2002-11-07 | 2002-11-07 | Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| US10/290,908 | 2002-11-07 | ||
| PCT/US2003/035510 WO2004043373A2 (en) | 2002-11-07 | 2003-11-07 | Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0316039A true BR0316039A (pt) | 2005-09-13 |
| BRPI0316039B1 BRPI0316039B1 (pt) | 2017-08-29 |
| BRPI0316039B8 BRPI0316039B8 (pt) | 2021-05-25 |
Family
ID=32312121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0316039-4A BRPI0316039B1 (pt) | 2002-11-07 | 2003-11-07 | N-acetylgalactosamine-4-sulfatase precursor, treatment methods using enzyme and methods for enzyme production and purification |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6866844B2 (pt) |
| EP (2) | EP1565209B1 (pt) |
| JP (1) | JP4459059B2 (pt) |
| CN (1) | CN100374157C (pt) |
| AR (1) | AR042019A1 (pt) |
| AU (1) | AU2003290642B2 (pt) |
| BR (1) | BRPI0316039B1 (pt) |
| CA (1) | CA2502928C (pt) |
| CY (1) | CY1116164T1 (pt) |
| DK (1) | DK2327414T3 (pt) |
| ES (2) | ES2445028T3 (pt) |
| HK (1) | HK1157215A1 (pt) |
| IL (1) | IL168435A (pt) |
| MX (1) | MXPA05004880A (pt) |
| PT (2) | PT2327414E (pt) |
| SI (1) | SI2327414T1 (pt) |
| TW (1) | TWI327919B (pt) |
| WO (1) | WO2004043373A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972124B2 (en) * | 2000-05-01 | 2005-12-06 | Biomarin Pharmaceuticals Inc. | Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| WO2007109155A2 (en) * | 2006-03-17 | 2007-09-27 | Biomarin Pharmaceutical Inc. | Assays for detection of antibodies to lysosomal enzymes |
| CN101539550B (zh) * | 2009-04-28 | 2012-05-23 | 李绍平 | 用于多糖的定性与定量分析方法 |
| UA115650C2 (uk) | 2010-06-25 | 2017-12-11 | Шае Хюмен Дженетік Терапіс, Інк. | Способи та композиції для доставки до цнс арилсульфатази а |
| PE20180130A1 (es) | 2010-06-25 | 2018-01-18 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a |
| CN103068999A (zh) * | 2010-08-20 | 2013-04-24 | 贝林格尔.英格海姆国际有限公司 | 通过在获自细胞培养物的液体中改变ph灭活蛋白酶的方法 |
| US9896715B2 (en) | 2011-12-20 | 2018-02-20 | Jcr Pharmaceuticals Co., Ltd. | Method for analyzing formyl glycine residue |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| WO2015035180A1 (en) * | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Method for chromatography reuse |
| FR3011468B1 (fr) * | 2013-10-04 | 2015-12-04 | Inventiva | Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose |
| WO2019045149A1 (en) * | 2017-08-31 | 2019-03-07 | Green Cross Corporation | PROCESS FOR PURIFYING SULFATASE PROTEIN |
| AR119264A1 (es) * | 2019-06-05 | 2021-12-09 | Genentech Inc | Método para reutilización de cromatografía |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL281225A (pt) | 1961-07-20 | |||
| US3472931A (en) | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
| US3891757A (en) | 1971-11-11 | 1975-06-24 | Alza Corp | Anaesthetic topical and percutaneous administration with selected promoters |
| SE387536B (sv) | 1973-03-13 | 1976-09-13 | Astra Laekemedel Ab | Forfarande for framstellning av en lokalanestetisk beredning |
| CA2443555C (en) | 2000-05-01 | 2016-07-19 | Christopher M. Starr | Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly |
-
2002
- 2002-11-07 US US10/290,908 patent/US6866844B2/en not_active Expired - Lifetime
-
2003
- 2003-11-07 PT PT100114214T patent/PT2327414E/pt unknown
- 2003-11-07 CA CA2502928A patent/CA2502928C/en not_active Expired - Lifetime
- 2003-11-07 AR ARP030104118A patent/AR042019A1/es not_active Application Discontinuation
- 2003-11-07 ES ES03783223.5T patent/ES2445028T3/es not_active Expired - Lifetime
- 2003-11-07 EP EP03783223.5A patent/EP1565209B1/en not_active Expired - Lifetime
- 2003-11-07 TW TW092131341A patent/TWI327919B/zh not_active IP Right Cessation
- 2003-11-07 BR BRPI0316039-4A patent/BRPI0316039B1/pt not_active IP Right Cessation
- 2003-11-07 SI SI200332419T patent/SI2327414T1/sl unknown
- 2003-11-07 WO PCT/US2003/035510 patent/WO2004043373A2/en active Application Filing
- 2003-11-07 MX MXPA05004880A patent/MXPA05004880A/es active IP Right Grant
- 2003-11-07 JP JP2004551853A patent/JP4459059B2/ja not_active Expired - Lifetime
- 2003-11-07 DK DK10011421.4T patent/DK2327414T3/en active
- 2003-11-07 EP EP10011421.4A patent/EP2327414B1/en not_active Expired - Lifetime
- 2003-11-07 PT PT37832235T patent/PT1565209E/pt unknown
- 2003-11-07 AU AU2003290642A patent/AU2003290642B2/en not_active Expired
- 2003-11-07 CN CNB2003801059229A patent/CN100374157C/zh not_active Expired - Lifetime
- 2003-11-07 ES ES10011421.4T patent/ES2533770T3/es not_active Expired - Lifetime
-
2005
- 2005-05-05 IL IL168435A patent/IL168435A/en active IP Right Grant
-
2006
- 2006-02-23 HK HK11111628.4A patent/HK1157215A1/xx not_active IP Right Cessation
-
2015
- 2015-04-03 CY CY20151100321T patent/CY1116164T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2327414B1 (en) | 2015-01-07 |
| DK2327414T3 (en) | 2015-04-13 |
| EP1565209A2 (en) | 2005-08-24 |
| US20040101524A1 (en) | 2004-05-27 |
| AU2003290642B2 (en) | 2008-07-10 |
| TW200427459A (en) | 2004-12-16 |
| PT1565209E (pt) | 2014-02-13 |
| ES2445028T3 (es) | 2014-02-27 |
| BRPI0316039B8 (pt) | 2021-05-25 |
| IL168435A (en) | 2014-07-31 |
| SI2327414T1 (sl) | 2015-05-29 |
| US6866844B2 (en) | 2005-03-15 |
| CY1116164T1 (el) | 2017-02-08 |
| EP2327414A1 (en) | 2011-06-01 |
| CN100374157C (zh) | 2008-03-12 |
| CA2502928A1 (en) | 2004-05-27 |
| EP1565209B1 (en) | 2013-11-06 |
| WO2004043373A2 (en) | 2004-05-27 |
| JP4459059B2 (ja) | 2010-04-28 |
| ES2533770T3 (es) | 2015-04-15 |
| PT2327414E (pt) | 2015-04-13 |
| WO2004043373A3 (en) | 2004-08-05 |
| BRPI0316039B1 (pt) | 2017-08-29 |
| AU2003290642A1 (en) | 2004-06-03 |
| EP1565209A4 (en) | 2008-01-02 |
| HK1157215A1 (en) | 2012-06-29 |
| AR042019A1 (es) | 2005-06-08 |
| CA2502928C (en) | 2013-07-16 |
| JP2006510356A (ja) | 2006-03-30 |
| TWI327919B (en) | 2010-08-01 |
| CN1726046A (zh) | 2006-01-25 |
| MXPA05004880A (es) | 2005-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL192078A0 (en) | Recombinant ??-l-iduronidase,methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof | |
| WO2004069190A3 (en) | Combination therapy for treating protein deficiency disorders | |
| BR0316039A (pt) | Precursor de n-acetilgalactosamina-4-sulfatase, métodos de tratamento usando a enzima e métodos para produção e purificação da enzima | |
| HRP20090058A2 (en) | Prodrugs of excitatory amino acids | |
| BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
| BR0011251A (pt) | Composições de a-beta peptìdeo e processos para a produção das mesmas | |
| MXPA05013564A (es) | Proteinas de fusion. | |
| MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
| WO2003032994A3 (de) | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren | |
| SG158731A1 (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| BR0014710A (pt) | Métodos para o tratamento de dor | |
| BR0316157A (pt) | Derivados de 4-amino-5-fenil-7-ciclohexil-pirrolo[2,3-d]pirimidina | |
| WO2002038775A3 (en) | METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE | |
| MXPA06000660A (es) | Uso de una composicion cosmetica o farmaceutica que comprende un extracto rico en lupeol, como un ingrediente activo para estimular la sintesis de proteinas de choque termico. | |
| UA86399C2 (ru) | Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза | |
| DE50305587D1 (en) | 2-heteroarylcarbonsäureamide | |
| BRPI0416434A (pt) | métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina | |
| BR9910323A (pt) | Alfa-l-iduronidase recombinante, métodos para produção e purificação da mesma e métodos para tratamento de doenças ocasionadas deficiência da mesma | |
| ATE402253T1 (de) | Humane adulte astrozyten, sowie deren herstellung und verwendung | |
| WO2001083722A3 (en) | Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly | |
| WO2004056768A3 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
| BG103512A (en) | Substituted pyramidine compounds and their application | |
| BRPI0408077A (pt) | composições e métodos para prevenção e tratamento de doenças relacionadas com endotoxina e condições | |
| MXPA02011162A (es) | Proteina cln2 recombinante de humano y metodos para su reduccion y uso. | |
| WO2001075021A3 (fr) | Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2800 DE 03/09/2024 POR TER SIDO INDEVIDA. |